



TasP

Ukuphila kwami, ukuphila kwethu

Africa Centre TasP Trial

SAE-AI

Serious Adverse Event Reporting

ANRS 12249 Initial SAE Notification

Completed forms must be sent to
ANRS within 48 hrs.
Email: pharmacovigilance@anrs.fr
Fax: +33 153 946 002



00317432

SAE No.

SAE Visit Date

20160318

Initial Notification Date

20160322

Notification time

1400

1. Patient details

TasP ID

51041

Name

N.Q.M.

Sex



Male

Female

Date of birth

19670721

Enrolment date

20150413

2. Measurements

Height

Cms

Last known: Weight

50.6

Kgs

Weight Date

20160229

CD4 count

535

CD4 Date

20151012

Viral Load

440

Viral Load Date

20151012

3. By which criteria is this adverse event considered to be "Serious"?

Tick all that apply



Resulted in death → Date of death

Probable cause



Life threatening (i.e. at risk of death at time of event)



Caused or prolonged hospitalisation (not elective hospitalisation for a pre-existing condition)



Persistent or significant disability / incapacity



Congenital abnormality / birth defect



Grade 4 clinical and biological events



Other serious, medically-important condition → Specify

4. Details of SAE


Enter each adverse event (e.g. symptom, sign, syndrome or diagnosis) on a separate line

Event Name

Date investigator
became aware

SIGNATURE:

Date of onset of SAE



1. Status Epilepticus 20160318 20160305

2.

3.

4.

5.

5. Description of SAE

Include details of body site, relevant laboratory tests, treatments received and relevant medical history.

Attach copies of any relevant hospital records, laboratory test results etc.

Participant in control cluster. Transferred in already on ART (Atrisco).
CD4 535; viral load suppressed. Recently reviewed by trial clinician for defaulting
anti-epileptic (Sodium Valproate) on 29/2/2016. Upon follow up; partner reports
participant had multiple seizures on 5/3/2016; became unconscious and has
been in hospital since then. More information to follow once he has been
discharged.

6. Medications

List all drugs taken (or prescribed) before occurrence of SAE

Generic Name	Daily dose	Route of administration	Indication	Date started	Date stopped	Causality assessment	Expected reaction? (BNF/SPC)	Action taken
1. Tenofovir	300mg	oral	HIV	2013 07 24		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
2. Emtricitabine	200mg	oral	HIV	2013 07 24		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
3. Efavirenz	600mg	oral	HIV	2013 07 24		<input checked="" type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input checked="" type="radio"/> No	<input checked="" type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
4.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
5.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop
6.						<input type="radio"/> Unrelated <input type="radio"/> Poss. related <input type="radio"/> Cannot be assessed	<input type="radio"/> Yes <input type="radio"/> No	<input type="radio"/> None <input type="radio"/> Reduce <input type="radio"/> Interrupt <input type="radio"/> Stop

7. Other causes of SAE, if unrelated to drugs mentioned in Section 6 above

7a. According to the physician, is this SAE likely to be related to participation in the research?

Yes ☐ No ☒

7b. According to the physician, is this SAE related to any causes other than the research?

This includes the patient's medical history

Yes ☒ No ☐

Describe

Participant defaulted anti-epileptic treatment and thus had seizures.

8. SAE Outcome

Died

Unknown to date

☒ Ongoing

Improved

Recovered

→ A complementary SAE notification must be submitted within 8 days

→ Date of recovery

Recovered without sequelae

or

Recovered with sequelae

→ Describe

Physician reporting SAE

Name

GUGLITHE MUKHUNSI

Signature

[Signature]

Date form completed

2016 03 22